ArticleBMJ (Clinical research ed.)2005
Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
Article in BMJ (Clinical research ed.), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 153 citations in OpenAlex.
- Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2008Trial
- A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip.Annals of the rheumatic diseases · 2007Trial
- Comparative effectiveness of generic commercial versus locally customized clinical decision support tools to reduce prescription of nonsteroidal anti-inflammatory drugs for patients with heart failure.Journal of the American Medical Informatics Association : JAMIA · 2023Article
- Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing.European heart journal. Cardiovascular pharmacotherapy · 2022Article
- Article
- Cardiovascular effects and safety of (non-aspirin) NSAIDs.Nature reviews. Cardiology · 2020Review
- Potentially harmful drug prescription in elderly patients with heart failure with reduced ejection fraction.ESC heart failure · 2020Article
- Observational
- Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.Korean circulation journal · 2017Review
- Adverse drug reaction-related hospitalisations among patients with heart failure at two hospitals in the United Arab Emirates.International journal of clinical pharmacy · 2015Observational
- Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice.Clinical drug investigation · 2013Review
- COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood.The open cardiovascular medicine journal · 2010Article
- Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly.European journal of clinical pharmacology · 2010Article
- Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.British journal of clinical pharmacology · 2010Article
- Differential impact of NSAIDs on rate of adverse events that require hospitalization in high-risk and general veteran populations: a retrospective cohort study.Drugs & aging · 2010Article
- Inhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins.Human molecular genetics · 2009Article
- Celecoxib in arthritis: relative risk management profile and implications for patients.Therapeutics and clinical risk management · 2009Article
- Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.British journal of clinical pharmacology · 2008Article
- NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans.Drug safety · 2008Article
- Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis.Core evidence · 2007Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the risk of death and recurrent congestive heart failure in elderly patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs (NSAIDs) and to determine whether there are class differences between celecoxib and rofecoxib.
designPopulation based retrospective cohort study.
settingDatabases of hospital discharge summaries and prescription drug claims in Quebec.
participants2256 patients aged 66 or more prescribed celecoxib, rofecoxib, or an NSAID after an index admission for congestive heart failure between April 2000 and March 2002.
main outcome measuresTime to all cause death and recurrent congestive heart failure, combined and separately.
resultsThe risk of death and recurrent congestive heart failure combined was higher in patients prescribed NSAIDs or rofexocib than in those prescribed celecoxib (hazard ratio 1.26, 95% confidence interval 1.00 to 1.57 and 1.27, 1.09 to 1.49, respectively). The findings were similar when the outcomes were assessed separately. In pairwise analysis, the risks of death and recurrent congestive heart failure, combined and separate, were similar between patients prescribed NSAIDs and rofecoxib.
conclusionsCelecoxib seems safer than rofecoxib and NSAIDs in elderly patients with congestive heart failure. Differences were found among cyclo-oxygenase-2 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.